SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Exclusion Criteria

• •Stage IV (metastatic) breast cancer.
• •Has received chemotherapy, endocrine therapy, targeted therapy, reflex therapy, etc. for this disease.
• •The patient has a second primary malignant tumor, except for fully treated skin cancer.
• •The patient had undergone major surgical procedures unrelated to breast cancer within 4 weeks before enrollment, or the patient has not fully recovered from such surgical procedures.
• •The presence of uncontrolled cardiovascular and cerebrovascular disease, including (but not limited to) any of the following within the 6 months prior to the first dose: congestive heart failure (NYHA III or IV), myocardial infarction or cerebral infarction, pulmonary embolism, unstable angina, or arrhythmia requiring treatment at the time of screening; Primary cardiomyopathy (e.g., dilated cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, restricted cardiomyopathy, undefined cardiomyopathy); A clinically significant history of prolonged QTc, grade II type II atrioventricular block or grade III atrioventricular block or QTc interphase (F method) \> 470 msec (female); Atrial fibrillation (EHRA grade ≥2b); Unmanageable hypertension, which the investigators judged unsuitable for study participation.
• •Due to serious and uncontrollable other medical diseases, researchers believe that there are contraindications to chemotherapy.
• •Individuals with a known history of allergies to the drug components of this protocol;
• •Having a history of immunodeficiency, including HIV testing positive, or suffering from other acquired or congenital immunodeficiency diseases, or having a history of organ transplantation.